Reimagining Treatments for Complex Disease
NED Biosystems™, a Delaware Public Benefit Corporation, has spent over 10 years reimagining treatment for cancer, culminating with the development of the patented NED-170 CANCER.
NED-170 CANCER is an investigational multi-faceted, combination, oral treatment designed to impact the major processes that drive cancer designed to improve outcomes with low toxicity.
NED-170 CANCER’s treatment goal is to fit the large unmet need for ~50% of patients for whom there is no genetically sequenced “match” therapy options.
Today, NED is deploying its multi-faceted methodology to develop NED-260 COVID to combat COVID-19 and its variants.
NED-260 COVID’s treatment goal is to act early in the infection process to minimize, or eliminate, the advancement to severe disease, allowing fewer patients to be hospitalized, ideally allowing many patients to recover at home.
NED-260 COVID and NED-170 CANCER strive to lessen the impact of two of the deadliest diseases faced by humanity today.